ZCZhe Jay Chen

Zhe Jay Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhe Jay Chen has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Editorial: Innovations, advances, and challenges in precision radiation oncology physics

    by Fada Guan, Lawrence Bronk, Jinbo Yue, Radhe Mohan, Zhe Chen


  • Open Access

    Characterization of GafchromicTM EBT4 film with clinical kV/MV photons and MeV electrons

    by Fada Guan, Huixiao Chen, Emily Draeger, Yuting Li, Resat Aydin, Christopher J. Tien, Zhe Chen

    Objective: A newly developed GafchromicTM EBT4 film model was released recently. According to the vendor‐stated specifications, this new model maintains major features of its more recent predecessor, EBT3, but has a great improvement in the signal‐to‐noise ratio (SNR). The purpose of this study was to fully characterize the EBT4 model by testing its dose response dependence on beam energy using clinical photon and electron beams and validating its improvement in SNR.Methods: In the beam energy dependence experiments, 6 MV and 15 MV photon beams, 6 MeV, 12 MeV and 20 MeV electron beams, 120 kVp and two 250 kVp x‐ray beams (with different half‐layer values) were selected, representing different clinical beam energies and radiation types. In the noise and SNR analyses, only the 6 MV photon beam was selected as the representative to compare between EBT4 and EBT3 models.Results: The energy dependence test results showed that there was a slight difference (10%) in the dose response was found for the 120 kVp x‐ray beam. For the two 250 kVp x‐ray beams, the difference in the dose response was moderate (<5%), but not negligible. The noise and SNR results showed a reduced noise and strengthened SNR in EBT4.Conclusion: We conclude that the EBT4 film has a minimal energy dependence for MV photon and MeV electron beams but has a notable energy dependence for kilovoltage x‐ray beams, and the vendor‐stated features of the reduced noise and improved SNR in EBT4 are validated.


  • Open Access

    Dosimetric response of Gafchromic™ EBT‐XD film to therapeutic protons

    by Fada Guan, Xiaochun Wang, Ming Yang, Emily Draeger, Dae Han, Kiminori Iga, Fanqing Guo, Luis Perles, Yuting Li, Narayan Sahoo, et al.

    The EBT‐XD model of Gafchromic™ films has a broader optimal dynamic dose range, up to 40 Gy, compared with its predecessor models. This characteristic has made EBT‐XD films suitable for high‐dose applications, such as stereotactic body radiotherapy and stereotactic radiosurgery, as well as ultra‐high dose rate FLASH radiotherapy. The purpose of the current study was to characterize the dependence of EBT‐XD film response on linear energy transfer (LET) and dose rate of therapeutic protons from a synchrotron. A clinical spot‐scanning proton beam was used to study LET dependence at three dose‐averaged LET values of 1.0 keV/μm, 3.6 keV/μm, and 7.6 keV/μm. A research proton beamline was used to study dose rate dependence at 150 Gy/s in the FLASH mode and 0.3 Gy/s in the non‐FLASH mode. Film response data from dose‐averaged LET values of 0.9 keV/μm and 9.0 keV/μm of the proton FLASH beam were also compared. Film response data from a clinical 6‐MV photon beam were used as a reference. Both the gray value method and optical density (OD) method were used in film calibration. Calibration results using a specific OD calculation method and a generic OD calculation method were compared. The four‐parameter NIH Rodbard function and three‐parameter rational function were compared in fitting the calibration curves. Experimental results showed that the response of EBT‐XD film is proton LET dependent, but independent of dose rate. Goodness‐of‐fit analysis showed that using the NIH Rodbard function is superior for both protons and photons. Using the “specific OD + NIH Rodbard function” method for EBT‐XD film calibration is recommended.


  • Open Access

    Frequency of errors in the transfer of treatment parameters from the treatment planning system to the oncology information system in a multi‐vendor environment

    by William P. Donahue, Emily Draeger, Dae Yup Han, Zhe Chen

    Background: Technological advancements have made it possible to improve patient outcomes in radiotherapy, sparing both normal tissues and increasing tumour control. However, these advancements have resulted in an increase in the number of software systems used, which each require data inputs to function. For institutions with multiple vendors for their treatment planning systems and oncology information systems, the transfer of data between them is potentially error prone and can lead to treatment errors.Purpose: The goal of this work was to determine the frequency of errors in data transfers between the Varian Eclipse treatment planning system and the Elekta Mosaiq oncology information system.Methods: An in‐house program was used to quantify the number of errors for 2700 unique plans over an 8‐month period. Using this information, the frequency of the errors were calculated. A risk priority number was calculated using the calculated frequencies to determine the impact on the clinic.Results: The most common errors discovered were backup timer settings (10.7%), Field label (8.5%), DRR associations (3.3%), imaging field types (3.1%), dose rate (1%), Field Id (0.8%), imaging isocenter (0.7% and SSD (0.7%). Based on the risk priority numbers, the DRR association error was ranked as having the highest potential impact on the patient.Conclusions: The results of the work show that the most effort should be focused on checking the manual steps performed in the transfer process, while items that are imported directly from DICOM‐RT without modification are highly likely to be transferred accurately. The data can be used to help guide the implementation of future automated tools and process improvement in the clinic.


  • Open Access

    A small footprint couch‐top support device for image‐guided radiotherapy of heavy patients

    by Huixiao Chen, Kevin Morley, Ronnie Rodriguez, Emily Draeger, Muhammad Shafiq Ul Hassan, Zhe (Jay) Chen

    Purpose: Patients with body weights close to or above 400 lbs present unique challenges in radiation therapy since the weight limit of most treatment couches decreases as the couch‐top extends toward the treatment gantry. The purpose of this work was to develop a small footprint couch‐top support platform to safely perform image‐guided radiotherapy (IGRT) for extremely heavy patients.Methods: One way to protect the couch‐top from damage and prevent a catastrophic breakdown is to provide additional support as the couch extends toward the treatment gantry. To allow a maximal range of gantry movement, a small‐footprint adjustable jack stand, placed underneath the couch‐top, was chosen and modified from a commercial jack stand (with 1100 lbs capacity). The couch could be easily extended longitudinally and laterally with a modified 8‐ball‐transfer plate mounted at the top. The operation of a couch‐top support platform was used for two heavy patients after phantom testing. kV and MV imaging options and ranges were quantified.Results: The custom‐constructed couch‐top support platform was found to provide stable support with smooth couch shifts. The small footprint allowed gantry rotation from 133° to 227°, which would allow both fixed beam radiotherapy and partial‐arc volumetric modulated arc therapy (VMAT). For IGRT, orthogonal 2D kV‐kV image pairs with source angles of 40o and 130o were acquired and tested successfully. With the support platform, two clinical cases with patient weights greater than 415 lbs were successfully treated with image‐guided partial arc VMAT radiotherapy. The study demonstrated the safety and efficiency of using this new couch‐top support platform to prevent couch failure from treating heavy patients.Conclusions: A new couch‐top support platform has been designed, assembled, and tested for IGRT. The new support platform is easy to use, cost‐effective, and allows extremely heavy patients to be treated safely and robustly with IGRT and VMAT.

  • Open Access

    Motion management in gastrointestinal cancers

    by Hassan Abbas, Bryan Chang, Zhe (Jay) Chen

    Motion management in gastrointestinal cancers


  • The impact of prostate edema on cell survival and tumor control after permanent interstitial brachytherapy for early stage prostate cancers

    by Zhe (Jay) Chen, Kenneth Roberts, Roy Decker, Pradip Pathare, Sara Rockwell, Ravinder Nath

    Previous studies have shown that procedure-induced prostate edema during permanent interstitial brachytherapy (PIB) can cause significant variations in the dose delivered to the prostate gland. Because the clinical impact of edema-induced dose variations strongly depends on the magnitude of the edema, the temporal pattern of its resolution and its interplay with the decay of radioactivity and the underlying biological processes of tumor cells (such as tumor potential doubling time), we investigated the impact of edema-induced dose variations on the tumor cell survival and tumor control probability after PIB with the (131)Cs, (125)I and (103)Pd sources used in current clinical practice. The exponential edema resolution model reported by Waterman et al (1998 Int. J. Radiat. Oncol. Biol. Phys. 41 1069-77) was used to characterize the edema evolutions previously observed during clinical PIB for prostate cancer. The concept of biologically effective dose, taking into account tumor cell proliferation and sublethal damage repair during dose delivery, was used to characterize the effects of prostate edema on cell survival and tumor control probability. Our calculation indicated that prostate edema, if not appropriately taken into account, can increase the cell survival and decrease the probability of local control of PIB. The magnitude of an edema-induced increase in cell survival increased with increasing edema severity, decreasing half-life of radioactive decay and decreasing photon energy emitted by the source. At the doses currently prescribed for PIB and for prostate cancer cells characterized by nominal radiobiology parameters recommended by AAPM TG-137, PIB using (125)I sources was less affected by edema than PIB using (131)Cs or (103)Pd sources due to the long radioactive decay half-life of (125)I. The effect of edema on PIB using (131)Cs or (103)Pd was similar. The effect of edema on (103)Pd PIB was slightly greater, even though the decay half-life of (103)Pd (17 days) is longer than that of (131)Cs (9.7 days), because the advantage of the longer (103)Pd decay half-life was negated by the lower effective energy of the photons it emits (∼21 keV compared to ∼30.4 keV for (131)Cs). In addition, the impact of edema could be reduced or enhanced by differences in the tumor characteristics (e.g. potential tumor doubling time or the α/β ratio), and the effect of these factors varied for the different radioactive sources. There is a clear need to consider the effects of prostate edema during the planning and evaluation of permanent interstitial brachytherapy treatments for prostate cancer.


  • A systematic evaluation of the dose-rate constant determined by photon spectrometry for 21 different models of low-energy photon-emitting brachytherapy sources

    by Zhe (Jay) Chen, Ravinder Nath

    The aim of this study was to perform a systematic comparison of the dose-rate constant (Λ) determined by the photon spectrometry technique (PST) with the consensus value ((CON)Λ) recommended by the American Association of Physicists in Medicine (AAPM) for 21 low-energy photon-emitting interstitial brachytherapy sources. A total of 63 interstitial brachytherapy sources (21 different models with 3 sources per model) containing either (125)I (14 models), (103)Pd (6 models) or (131)Cs (1 model) were included in this study. A PST described by Chen and Nath (2007 Med. Phys. 34 1412-30) was used to determine the dose-rate constant ((PST)Λ) for each source model. Source-dependent variations in (PST)Λ were analyzed systematically against the spectral characteristics of the emitted photons and the consensus values recommended by the AAPM brachytherapy subcommittee. The values of (PST)Λ for the encapsulated sources of (103)Pd, (125)I and (131)Cs varied from 0.661 to 0.678 cGyh(-1) U(-1), 0.959 to 1.024 cGyh(-1)U(-1) and 1.066 to 1.073 cGyh(-1)U(-1), respectively. The relative variation in (PST)Λ among the six (103)Pd source models, caused by variations in photon attenuation and in spatial distributions of radioactivity among the source models, was less than 3%. Greater variations in (PST)Λ were observed among the 14 (125)I source models; the maximum relative difference was over 6%. These variations were caused primarily by the presence of silver in some (125)I source models and, to a lesser degree, by the variations in photon attenuation and in spatial distribution of radioactivity among the source models. The presence of silver generates additional fluorescent x-rays with lower photon energies which caused the (PST)Λ value to vary from 0.959 to 1.019 cGyh(-1)U(-1) depending on the amount of silver used by a given source model. For those (125)I sources that contain no silver, their (PST)Λ was less variable and had values within 1% of 1.024 cGyh(-1)U(-1). For the 16 source models that currently have an AAPM recommended (CON)Λ value, the agreement between (PST)Λ and (CON)Λ was less than 2% for 15 models and was 2.6% for 1 (103)Pd source model. Excellent agreement between (PST)Λ and (CON)Λ was observed for all source models that currently have an AAPM recommended consensus dose-rate constant value. These results demonstrate that the PST is an accurate and robust technique for the determination of the dose-rate constant for low-energy brachytherapy sources.


  • Impact of source-production revision on the dose-rate constant of C131s interstitial brachytherapy sources

    by Zhe Jay Chen, Paul Bongiorni, Ravinder Nath

    Since its introduction in 2004, the model CS-1 Rev.1 131Cs source has been used in many radiation therapy clinics for prostate brachytherapy. In 2006, this source model underwent a Rev.2 production revision. The aim of this work was to investigate the dosimetric influences of the Rev.2 production revision using high-resolution photon spectrometry. Three CS-1 Rev.1 and three CS-1 Rev.2 131Cs sources were used in this study. The relative photon energy spectrum emitted by each source in the transverse bisector of the source was measured using a high-resolution germanium detector designed for low-energy photon spectrometry. Based on the measured photon energy spectrum and the radioactivity distribution in the source, the dose-rate constant (lamda) of each source was determined. The effects of the Rev.2 production revision were quantified by comparing the emitted photon energy spectra and the lamda values determined for the sources manufactured before and after the production revision. The relative photon energy spectrum originating from the principal emissions of 131Cs was found to be nearly identical before and after the Rev.2 revision. However, the portion of the spectrum originating from the production of fluorescent x rays in niobium, a trace element present in the source construction materials, was found to differ significantly between the Rev.1 and Rev.2 sources. The peak intensity of the Nb Kalpha and Nb Kbeta fluorescent x rays from the Rev.2 source was approximately 35% of that from the Rev.1 source. Consequently, the nominal lamda value of the Rev.2 source was found to be greater than that determined for the Rev.1 source by approximately 0.7% +/- 0.5%. A significant reduction (65%) in relative niobium fluorescent x-ray yield was observed in the Rev.2 131Cs sources. The impact of this reduction on the dose-rate constant was found to be small, with a relative difference of less than 1%. This study demonstrates that photon spectrometry can be used as a sensitive and convenient tool for monitoring and for quantifying the dosimetric effects of brachytherapy source-production revisions. Because production revision can change both the geometry and the atomic composition of brachytherapy sources, its dosimetric impact should be carefully monitored and evaluated for each production revision.